Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 11/2016

06.09.2016 | Original Article – Cancer Research

The activity and tissue distribution of thioredoxin reductase in basal cell carcinoma

verfasst von: Maryam Sobhani, Ahmad-Reza Taheri, Amir-Hossein Jafarian, Seyed Isaac Hashemy

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Basal cell carcinoma (BCC) is the most prevalent cancer worldwide. Different mechanisms are proposed to be involved in its pathogenesis such as oxidative stress. Oxidative stress, which is the consequence of the disruption of redox balance in favor of oxidants, is involved in the initiation or progression of many tumors. Thioredoxin reductase (TrxR) is a key enzyme of the thioredoxin (Trx) system, containing Trx and TrxR and NADPH, which is one of the main cellular oxidoreductases with an essential role in cellular health and survival through providing and maintaining redox balance. Therefore, we aimed to study and compare the activity and tissue distribution of TrxR in tumoral tissue and its healthy margin in patients with BCC.

Methods

After biopsy and taking samples from 18 patients, TrxR activity was measured using a commercial kit and its tissue distribution was assessed immunohistochemically.

Results

Both the activity and tissue distribution of TrxR in tumoral tissues were significantly higher compared to their healthy margins. Regarding the tissue distribution, this significant increase in TrxR in tumoral tissues was documented based on both staining intensity and abundance of positive cells in immunohistochemistry.

Conclusions

Based on these results, it is concluded that TrxR is involved in the pathogenesis of BCC; however, more investigations are required to clarify whether this increase is a consequence of BCC or it is an initiating mechanism.
Literatur
Zurück zum Zitat Amirchaghmaghi M et al (2016) Evaluation of plasma isoprostane in patients with oral lichen planus. J Dent 17:21–25 Amirchaghmaghi M et al (2016) Evaluation of plasma isoprostane in patients with oral lichen planus. J Dent 17:21–25
Zurück zum Zitat Cheraskin E (1996) Antioxidants in health and disease. J Am Optom Assoc 67:50–57PubMed Cheraskin E (1996) Antioxidants in health and disease. J Am Optom Assoc 67:50–57PubMed
Zurück zum Zitat Cretnik M et al (2009) Involvement of p16 and PTCH in pathogenesis of melanoma and basal cell carcinoma. Int J Oncol 34:1045–1050PubMed Cretnik M et al (2009) Involvement of p16 and PTCH in pathogenesis of melanoma and basal cell carcinoma. Int J Oncol 34:1045–1050PubMed
Zurück zum Zitat Deng M, Marsch AF, Petronic-Rosic V (2015) Basal cell carcinoma: part 1—basal cell carcinoma has come of age. Skinmed 13:206–213; quiz 214 Deng M, Marsch AF, Petronic-Rosic V (2015) Basal cell carcinoma: part 1—basal cell carcinoma has come of age. Skinmed 13:206–213; quiz 214
Zurück zum Zitat Dhalla NS, Temsah RM, Netticadan T (2000) Role of oxidative stress in cardiovascular diseases. J Hypertens 18:655–673CrossRefPubMed Dhalla NS, Temsah RM, Netticadan T (2000) Role of oxidative stress in cardiovascular diseases. J Hypertens 18:655–673CrossRefPubMed
Zurück zum Zitat Didier C, Kerblat I, Drouet C, Favier A, Beani JC, Richard MJ (2001) Induction of thioredoxin by ultraviolet: a radiation prevents oxidative-mediated cell death in human skin fibroblasts. Free Radic Biol Med 31:585–598CrossRefPubMed Didier C, Kerblat I, Drouet C, Favier A, Beani JC, Richard MJ (2001) Induction of thioredoxin by ultraviolet: a radiation prevents oxidative-mediated cell death in human skin fibroblasts. Free Radic Biol Med 31:585–598CrossRefPubMed
Zurück zum Zitat Goppner D, Leverkus M (2011) Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease. J Skin Cancer 2011:650258. doi:10.1155/2011/650258 PubMed Goppner D, Leverkus M (2011) Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease. J Skin Cancer 2011:650258. doi:10.​1155/​2011/​650258 PubMed
Zurück zum Zitat Gupta RK et al (2014) Oxidative stress and antioxidants in disease and cancer: a review. Asian Pac J Cancer Prev: APJCP 15:4405–4409CrossRefPubMed Gupta RK et al (2014) Oxidative stress and antioxidants in disease and cancer: a review. Asian Pac J Cancer Prev: APJCP 15:4405–4409CrossRefPubMed
Zurück zum Zitat Hashemy SI (2011) The human thioredoxin system: modifications and clinical applications. Iran J Basic Med Sci 14:191–204 Hashemy SI (2011) The human thioredoxin system: modifications and clinical applications. Iran J Basic Med Sci 14:191–204
Zurück zum Zitat Hashemy SI, Gharaei S, Vasigh S, Kargozar S, Alirezaei B, Keyhani FJ, Amirchaghmaghi M (2016) Oxidative stress factors and C-reactive protein in patients with oral lichen planus before and 2 weeks after treatment. J Oral Pathol Med 45:35–40. doi:10.1111/jop.12326 CrossRefPubMed Hashemy SI, Gharaei S, Vasigh S, Kargozar S, Alirezaei B, Keyhani FJ, Amirchaghmaghi M (2016) Oxidative stress factors and C-reactive protein in patients with oral lichen planus before and 2 weeks after treatment. J Oral Pathol Med 45:35–40. doi:10.​1111/​jop.​12326 CrossRefPubMed
Zurück zum Zitat Kaffe ET, Rigopoulou EI, Koukoulis GK, Dalekos GN, Moulas AN (2015) Oxidative stress and antioxidant status in patients with autoimmune liver diseases Redox report: communications in free radical research 20:33–41. doi:10.1179/1351000214Y.0000000101 PubMed Kaffe ET, Rigopoulou EI, Koukoulis GK, Dalekos GN, Moulas AN (2015) Oxidative stress and antioxidant status in patients with autoimmune liver diseases Redox report: communications in free radical research 20:33–41. doi:10.​1179/​1351000214Y.​0000000101 PubMed
Zurück zum Zitat Kilic N, Yavuz Taslipinar M, Guney Y, Tekin E, Onuk E (2014) An investigation into the serum thioredoxin, superoxide dismutase, malondialdehyde, and advanced oxidation protein products in patients with breast cancer. Ann Surg Oncol 21:4139–4143. doi:10.1245/s10434-014-3859-3 CrossRefPubMed Kilic N, Yavuz Taslipinar M, Guney Y, Tekin E, Onuk E (2014) An investigation into the serum thioredoxin, superoxide dismutase, malondialdehyde, and advanced oxidation protein products in patients with breast cancer. Ann Surg Oncol 21:4139–4143. doi:10.​1245/​s10434-014-3859-3 CrossRefPubMed
Zurück zum Zitat Kumar S, Holmgren A (1999) Induction of thioredoxin, thioredoxin reductase and glutaredoxin activity in mouse skin by TPA, a calcium ionophore and other tumor promoters. Carcinogenesis 20:1761–1767CrossRefPubMed Kumar S, Holmgren A (1999) Induction of thioredoxin, thioredoxin reductase and glutaredoxin activity in mouse skin by TPA, a calcium ionophore and other tumor promoters. Carcinogenesis 20:1761–1767CrossRefPubMed
Zurück zum Zitat Milkovic L, Siems W, Siems R, Zarkovic N (2014) Oxidative stress and antioxidants in carcinogenesis and integrative therapy of cancer. Curr Pharm Des 20:6529–6542CrossRefPubMed Milkovic L, Siems W, Siems R, Zarkovic N (2014) Oxidative stress and antioxidants in carcinogenesis and integrative therapy of cancer. Curr Pharm Des 20:6529–6542CrossRefPubMed
Zurück zum Zitat Nakamura H et al (2000) Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev 24:53–60PubMed Nakamura H et al (2000) Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev 24:53–60PubMed
Zurück zum Zitat Nazoury M, Hosseini-Zijoud SM, Soukhtanloo M, Mashkani B, Hashemy SI (2014) Determination of in vitro and in vivo protective effects of Ghrelin against oxidative stress: experimental study. J Appl Pharm Sci 4:008–013. doi:10.7324/JAPS.2014.41202 Nazoury M, Hosseini-Zijoud SM, Soukhtanloo M, Mashkani B, Hashemy SI (2014) Determination of in vitro and in vivo protective effects of Ghrelin against oxidative stress: experimental study. J Appl Pharm Sci 4:008–013. doi:10.​7324/​JAPS.​2014.​41202
Zurück zum Zitat Niu BZ, Chen G, Li LJ, Wu YD, Zhao YP (2005) [Drug resistance and activity changes of thioredoxin reductase in pancreatic cancer cells strain SW1990 induced by gemcitabine] Zhongguo yi xue ke xue yuan xue bao. Acta Acad Med Sin 27:606–610 Niu BZ, Chen G, Li LJ, Wu YD, Zhao YP (2005) [Drug resistance and activity changes of thioredoxin reductase in pancreatic cancer cells strain SW1990 induced by gemcitabine] Zhongguo yi xue ke xue yuan xue bao. Acta Acad Med Sin 27:606–610
Zurück zum Zitat Sander CS, Hamm F, Elsner P, Thiele JJ (2003) Oxidative stress in malignant melanoma and non-melanoma skin cancer. Br J Dermatol 148:913–922CrossRefPubMed Sander CS, Hamm F, Elsner P, Thiele JJ (2003) Oxidative stress in malignant melanoma and non-melanoma skin cancer. Br J Dermatol 148:913–922CrossRefPubMed
Zurück zum Zitat Shimizu M, Saitoh Y, Itoh H (1990) Immunohistochemical staining of Ha-ras oncogene product in normal, benign, and malignant human pancreatic tissues. Hum Pathol 21:607–612CrossRefPubMed Shimizu M, Saitoh Y, Itoh H (1990) Immunohistochemical staining of Ha-ras oncogene product in normal, benign, and malignant human pancreatic tissues. Hum Pathol 21:607–612CrossRefPubMed
Zurück zum Zitat Smith AD, Levander OA (2002) High-throughput 96-well microplate assays for determining specific activities of glutathione peroxidase and thioredoxin reductase. Methods Enzymol 347:113–121CrossRefPubMed Smith AD, Levander OA (2002) High-throughput 96-well microplate assays for determining specific activities of glutathione peroxidase and thioredoxin reductase. Methods Enzymol 347:113–121CrossRefPubMed
Zurück zum Zitat Stroes ES, Rabelink TJ, Van Faassen EE (1998) Redox state and health: a persisting challenge. Eur J Clin Invest 28:884–885CrossRefPubMed Stroes ES, Rabelink TJ, Van Faassen EE (1998) Redox state and health: a persisting challenge. Eur J Clin Invest 28:884–885CrossRefPubMed
Zurück zum Zitat Taheri A, Tanipour MH, Khorasani ZK, Kiafar B, Layegh P, Hashemy SI (2016) Serum protein carbonyl and total antioxidant capacity levels in pemphigus vulgaris and bullous pemphigoid Iranian. J Dermatol 18:156–162 Taheri A, Tanipour MH, Khorasani ZK, Kiafar B, Layegh P, Hashemy SI (2016) Serum protein carbonyl and total antioxidant capacity levels in pemphigus vulgaris and bullous pemphigoid Iranian. J Dermatol 18:156–162
Zurück zum Zitat Vural P, Canbaz M, Selcuki D (1999) Plasma antioxidant defense in actinic keratosis and basal cell carcinoma. J Eur Acad Dermatol Venereol: JEADV 13:96–101CrossRefPubMed Vural P, Canbaz M, Selcuki D (1999) Plasma antioxidant defense in actinic keratosis and basal cell carcinoma. J Eur Acad Dermatol Venereol: JEADV 13:96–101CrossRefPubMed
Metadaten
Titel
The activity and tissue distribution of thioredoxin reductase in basal cell carcinoma
verfasst von
Maryam Sobhani
Ahmad-Reza Taheri
Amir-Hossein Jafarian
Seyed Isaac Hashemy
Publikationsdatum
06.09.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 11/2016
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-016-2242-0

Weitere Artikel der Ausgabe 11/2016

Journal of Cancer Research and Clinical Oncology 11/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.